2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
| 近期推荐： | 热 Wiley 2026暑期线上学习营 | 报名正式开启！ | 热 多本ABS四星！优质经管国际期刊列表 | 热 全流程投稿协助套餐服务 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | JOURNAL OF CLINICAL ONCOLOGY J CLIN ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.9
53人评分
我要评分
声誉 9.9 影响力 9.9 速度 9.1 | |||||||||||||||||||||
| 期刊ISSN | 0732-183X | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1527-7755 | |||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：42.85 | |||||||||||||||||||||
| 2025-2026自引率 | 1.6%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 41.302数据由网友[等待runner]收集提供 | |||||||||||||||||||||
| h-index | 494 | |||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://jco.ascopubs.org/ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/JCO-ASCOPUBS | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Signal Worth Trusting-If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno Author: Lu, Yongkai Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 18, pp. 1745-1746. DOI: 10.1200/JCO-25-03015 Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study Author: Li, Wei; Zhang, Yongchang; Fan, Huijie; Yu, Qitao; Ran, Feiwu; Chen, Wenfeng; Zhou, Caicun Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 18, pp. 1670-1675. DOI: 10.1200/JCO-26-00434 Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS Author: Huang, Jian; Xie, Zheng-Fu Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 18, pp. 1747-1748. DOI: 10.1200/JCO-25-02755 Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study Author: Oberstein, Paul E.; Hecht, J. Randolph; Raghav, Kanwal; Pietrantonio, Filippo; Arnold, Dirk; Moreno, Victor; Van Cutsem, Eric; Malik, Rozita Abdul; Hong, Yong Sang; Lee, Myung Ah; Yu-Li Su, Harvey; Lee, Jeeyun; Chandana, Sreenivasa; Cruz-Correa, Marcia; Yuan, Ying; Ahmad, Azura; Lai, Kuan-Ming; Hsu, Hung-Chih; Chen, Eric Xueyu; Elez, Elena; Lin, Chia-Chi; Lopez, Carlos; Prenen, Hans; Rosello-Keranen, Susana; Velez, Hector; Yeh, Yu-Min; Heinemann, Volker; Eng, Cathy; Beom, Seung-Hoon; Tejpar, Sabine; Chowdhury, Sanjib; Lyu, Xuesong; Kamat, Medha; Curtin, Joshua C.; Patel, Bharvin; Xie, John; Bhattacharya, Rianka; Schnepp, Robert W.; Yilmaz, Emrullah; Iwasawa, Ryota; Daksh, Mahesh; Lorenzini, Patricia; Thayu, Meena; Baig, Mahadi; Kim, Han Sang; Han, Sae-Won Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 17, pp. 1624-1634. DOI: 10.1200/JCO-25-02187 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足JOURNAL OF CLINICAL ONCOLOGY的语言要求，还能让JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, USA, VA, 22314 | |||||||||||||||||||||
| 出版商 | American Society of Clinical Oncology | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Biweekly | |||||||||||||||||||||
| 出版年份 | 1983 | |||||||||||||||||||||
| 年文章数 | 308点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 36.39% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 97.08% | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
  | ||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0732-183X%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约20% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在JOURNAL OF CLINICAL ONCOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Signal Worth Trusting-If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno Author: Lu, Yongkai Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 18, pp. 1745-1746. DOI: 10.1200/JCO-25-03015 PubMed DOI |
| 2. | Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study Author: Li, Wei; Zhang, Yongchang; Fan, Huijie; Yu, Qitao; Ran, Feiwu; Chen, Wenfeng; Zhou, Caicun Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 18, pp. 1670-1675. DOI: 10.1200/JCO-26-00434 PubMed DOI |
| 3. | Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS Author: Huang, Jian; Xie, Zheng-Fu Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 18, pp. 1747-1748. DOI: 10.1200/JCO-25-02755 PubMed DOI |
| 4. | Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study Author: Oberstein, Paul E.; Hecht, J. Randolph; Raghav, Kanwal; Pietrantonio, Filippo; Arnold, Dirk; Moreno, Victor; Van Cutsem, Eric; Malik, Rozita Abdul; Hong, Yong Sang; Lee, Myung Ah; Yu-Li Su, Harvey; Lee, Jeeyun; Chandana, Sreenivasa; Cruz-Correa, Marcia; Yuan, Ying; Ahmad, Azura; Lai, Kuan-Ming; Hsu, Hung-Chih; Chen, Eric Xueyu; Elez, Elena; Lin, Chia-Chi; Lopez, Carlos; Prenen, Hans; Rosello-Keranen, Susana; Velez, Hector; Yeh, Yu-Min; Heinemann, Volker; Eng, Cathy; Beom, Seung-Hoon; Tejpar, Sabine; Chowdhury, Sanjib; Lyu, Xuesong; Kamat, Medha; Curtin, Joshua C.; Patel, Bharvin; Xie, John; Bhattacharya, Rianka; Schnepp, Robert W.; Yilmaz, Emrullah; Iwasawa, Ryota; Daksh, Mahesh; Lorenzini, Patricia; Thayu, Meena; Baig, Mahadi; Kim, Han Sang; Han, Sae-Won Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 17, pp. 1624-1634. DOI: 10.1200/JCO-25-02187 PubMed DOI |
| 5. | Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial Author: Gao, Hong-Fei; Ye, Guo-Lin; Lin, Ying; Huang, Qin; Dong, Jie; Cao, Yin; Zhao, Yan-Xia; Chen, Qian-Jun; Ma, Shi-Hui; Ouyang, Jie; Ye, Jin-Hui; Yang, Hua-Wei; Zhang, Yuan-Qi; Zhang, Yong-Cheng; Zhang, Gang-Ling; Li, Wei; Zhang, Yunjian; Wu, Zhi-Yong; Lin, Ying-Yi; Zhu, Teng; Zhang, Liu-Lu; Yang, Ci-Qiu; Yang, Mei; Peng, Hao; Chen, Bo; Chen, Yi-Tian; Ji, Fei; Cheng, Min-Yi; Li, Jie-Qing; Jiang, Zefei; Wang, Kun Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 17, pp. 1587-1596. DOI: 10.1200/JCO-25-02176 PubMed DOI |
| 6. | HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+Metastatic Breast Cancer Author: Dieras, Veronique; Curigliano, Giuseppe; Martin, Miguel; Lerebours, Florence; Tsurutani, Junji; Savard, Marie-France; Jerzak, Katarzyna J.; Hu, Xichun; Martins de Aquino Pimentel, Luciana Carla; O'Sullivan, Ciara C.; Tokunaga, Eriko; Okines, Alicia; Huang, Chiun-Sheng; Jacot, William; Sohn, Joohyuk; Cronemberger Silva, Eduardo; Mueller, Volkmar; Yang, Shan; Granata, Giovanna; Shen, Qi; Santarpia, Libero; Hamilton, Erika Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 17, pp. 1597-1607. DOI: 10.1200/JCO-25-02600 PubMed DOI |
| 7. | A phase III, randomized, open-label study of tunlametinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated BRAFV600E-mutant metastatic colorectal cancer Author: Xu, Ting; Li, Jian; Wang, Jufeng; Deng, Yanhong; Meng, Qiu; Niu, Zuoxing; Fan, Nanfeng; Yuan, Xianglin; Deng, Jun; Fang, Xuefeng; Zhang, Yanqiao; Tian, Hongqi; Liu, Wenbin; Shen, Lin Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 17_SUPPL, pp. LBA3509-LBA3509. DOI: 10.1200/JCO.2026.44.17_suppl.LBA3509 DOI |
| 8. | Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by D2 gastrectomy and adjuvant chemotherapy for locally advanced gastric cancer (Neo-CRAG): A randomized, multicenter, phase 3 trial Author: Xu, Rui-Hua; Wang, Wei; Zhang, Yu-Jing; Li, Yong; Li, Yong-Xiang; Zhao, Yan; Liang, Han; Chen, Jian-Si; Wan, Jin; Du, Yian; Wang, Zhenning; Zhao, Ping; Zhang, Jian; Zhou, Yanbing; Jin, Jing; Li, Yuan-fang; Zhou, Zhiwei Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 17_SUPPL, pp. LBA4075-LBA4075. DOI: 10.1200/JCO.2026.44.17_suppl.LBA4075 DOI |
| 9. | Efficacy and safety of fruquintinib combined with chemotherapy versus bevacizumab combined with chemotherapy as second-line treatment for metastatic colorectal cancer: A prospective, multicenter, randomized controlled trial Author: Xu, Jianmin; Chang, Wenju; Liu, Yu; Zhang, Zizhen; Yuan, Ying; Zhao, Ren; Chen, Xiaobing; Qin, Zhiquan; Song, Zhangfa; Wang, Guiying; Dai, Yong; Xu, Yanchang; Mao, Yong; Zhu, Lingjun; Rao, Shengxiang; Liang, Fei Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 17_SUPPL, pp. LBA3563-LBA3563. DOI: 10.1200/JCO.2026.44.17_suppl.LBA3563 DOI |
| 10. | A phase III CHIPRO study of chiauranib plus weekly paclitaxel for platinum-resistant or refractory ovarian cancer Author: Wu, Xiaohua; Li, Jin; Wang, Danbo; Wu, Jin; Zou, Dongling; Duan, Wei; Li, Dan; Yang, Hongying; Wu, Jingna; Xiong, Yuanhuan; Yan, Xiaojian; Li, Xiumin; Zhu, Genhai; Sun, Li; Li, Yuzhi; Liu, Qing; Kang, Yu; Wang, Ke; Zhang, Jieqing; Wang, Li Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 17_SUPPL, pp. LBA5504-LBA5504. DOI: 10.1200/JCO.2026.44.17_suppl.LBA5504 DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共117条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
